vs

Side-by-side financial comparison of Enovis CORP (ENOV) and Stride, Inc. (LRN). Click either name above to swap in a different company.

Stride, Inc. is the larger business by last-quarter revenue ($629.9M vs $548.9M, roughly 1.1× Enovis CORP). Stride, Inc. runs the higher net margin — 14.1% vs -104.1%, a 118.1% gap on every dollar of revenue. On growth, Stride, Inc. posted the faster year-over-year revenue change (2.7% vs -2.2%). Over the past eight quarters, Enovis CORP's revenue compounded faster (9.8% CAGR vs 6.9%).

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

Stride, Inc. is a for-profit education company that provides online and blended education programs. Stride, Inc. is an education management organization (EMO) that provides online education designed as an alternative to traditional "brick and mortar" education for public school students from kindergarten to 12th grade, as well as career learning programs. As of 2012, publicly traded Stride, Inc. was the largest EMO in terms of enrollment.

ENOV vs LRN — Head-to-Head

Bigger by revenue
LRN
LRN
1.1× larger
LRN
$629.9M
$548.9M
ENOV
Growing faster (revenue YoY)
LRN
LRN
+4.9% gap
LRN
2.7%
-2.2%
ENOV
Higher net margin
LRN
LRN
118.1% more per $
LRN
14.1%
-104.1%
ENOV
Faster 2-yr revenue CAGR
ENOV
ENOV
Annualised
ENOV
9.8%
6.9%
LRN

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
ENOV
ENOV
LRN
LRN
Revenue
$548.9M
$629.9M
Net Profit
$-571.1M
$88.5M
Gross Margin
59.9%
Operating Margin
-101.7%
20.5%
Net Margin
-104.1%
14.1%
Revenue YoY
-2.2%
2.7%
Net Profit YoY
18.8%
8.5%
EPS (diluted)
$-9.99
$1.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENOV
ENOV
LRN
LRN
Q3 26
$629.9M
Q4 25
$548.9M
$631.3M
Q3 25
$564.5M
$620.9M
Q2 25
$558.8M
$653.6M
Q1 25
$613.4M
Q4 24
$561.0M
$587.2M
Q3 24
$505.2M
$551.1M
Q2 24
$525.2M
Net Profit
ENOV
ENOV
LRN
LRN
Q3 26
$88.5M
Q4 25
$-571.1M
$99.5M
Q3 25
$-36.7M
$68.8M
Q2 25
$-56.0M
$51.3M
Q1 25
$99.3M
Q4 24
$-703.2M
$96.4M
Q3 24
$-31.5M
$40.9M
Q2 24
$-18.6M
Gross Margin
ENOV
ENOV
LRN
LRN
Q3 26
Q4 25
59.9%
41.1%
Q3 25
59.3%
39.0%
Q2 25
59.5%
36.6%
Q1 25
40.6%
Q4 24
54.8%
40.8%
Q3 24
56.7%
39.2%
Q2 24
55.0%
Operating Margin
ENOV
ENOV
LRN
LRN
Q3 26
20.5%
Q4 25
-101.7%
23.3%
Q3 25
-3.0%
11.1%
Q2 25
-8.4%
8.7%
Q1 25
21.3%
Q4 24
-118.5%
21.3%
Q3 24
-6.3%
8.6%
Q2 24
-8.4%
Net Margin
ENOV
ENOV
LRN
LRN
Q3 26
14.1%
Q4 25
-104.1%
15.8%
Q3 25
-6.5%
11.1%
Q2 25
-10.0%
7.9%
Q1 25
16.2%
Q4 24
-125.4%
16.4%
Q3 24
-6.2%
7.4%
Q2 24
-3.5%
EPS (diluted)
ENOV
ENOV
LRN
LRN
Q3 26
$1.93
Q4 25
$-9.99
$2.12
Q3 25
$-0.64
$1.40
Q2 25
$-0.98
$0.96
Q1 25
$2.02
Q4 24
$-12.69
$2.03
Q3 24
$-0.58
$0.94
Q2 24
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENOV
ENOV
LRN
LRN
Cash + ST InvestmentsLiquidity on hand
$33.6M
$614.0M
Total DebtLower is stronger
$1.4B
$417.6M
Stockholders' EquityBook value
$2.0B
$1.6B
Total Assets
$4.4B
$2.4B
Debt / EquityLower = less leverage
0.67×
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENOV
ENOV
LRN
LRN
Q3 26
$614.0M
Q4 25
$33.6M
$625.7M
Q3 25
$44.1M
$715.1M
Q2 25
$38.5M
$985.3M
Q1 25
$723.7M
Q4 24
$48.2M
$717.5M
Q3 24
$35.4M
$522.2M
Q2 24
$35.0M
Total Debt
ENOV
ENOV
LRN
LRN
Q3 26
$417.6M
Q4 25
$1.4B
$417.2M
Q3 25
$1.4B
$416.8M
Q2 25
$1.4B
$416.3M
Q1 25
$415.9M
Q4 24
$1.3B
$415.5M
Q3 24
$1.3B
$415.1M
Q2 24
$1.3B
Stockholders' Equity
ENOV
ENOV
LRN
LRN
Q3 26
$1.6B
Q4 25
$2.0B
$1.5B
Q3 25
$2.6B
$1.5B
Q2 25
$2.6B
$1.5B
Q1 25
$1.4B
Q4 24
$2.6B
$1.3B
Q3 24
$3.3B
$1.2B
Q2 24
$3.3B
Total Assets
ENOV
ENOV
LRN
LRN
Q3 26
$2.4B
Q4 25
$4.4B
$2.3B
Q3 25
$5.0B
$2.3B
Q2 25
$4.9B
$2.3B
Q1 25
$2.2B
Q4 24
$4.7B
$2.1B
Q3 24
$5.6B
$2.0B
Q2 24
$5.4B
Debt / Equity
ENOV
ENOV
LRN
LRN
Q3 26
0.25×
Q4 25
0.67×
0.27×
Q3 25
0.54×
0.27×
Q2 25
0.53×
0.28×
Q1 25
0.29×
Q4 24
0.52×
0.32×
Q3 24
0.40×
0.34×
Q2 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENOV
ENOV
LRN
LRN
Operating Cash FlowLast quarter
$82.6M
$117.0M
Free Cash FlowOCF − Capex
$29.1M
FCF MarginFCF / Revenue
5.3%
Capex IntensityCapex / Revenue
9.7%
Cash ConversionOCF / Net Profit
1.32×
TTM Free Cash FlowTrailing 4 quarters
$22.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENOV
ENOV
LRN
LRN
Q3 26
$117.0M
Q4 25
$82.6M
$91.8M
Q3 25
$47.8M
$-195.8M
Q2 25
$-1.6M
$298.3M
Q1 25
$53.1M
Q4 24
$88.3M
$223.4M
Q3 24
$53.6M
$-142.0M
Q2 24
$7.8M
Free Cash Flow
ENOV
ENOV
LRN
LRN
Q3 26
Q4 25
$29.1M
$91.6M
Q3 25
$3.4M
$-196.1M
Q2 25
$-44.9M
$297.9M
Q1 25
$52.9M
Q4 24
$35.1M
$222.9M
Q3 24
$2.4M
$-142.7M
Q2 24
$-31.6M
FCF Margin
ENOV
ENOV
LRN
LRN
Q3 26
Q4 25
5.3%
14.5%
Q3 25
0.6%
-31.6%
Q2 25
-8.0%
45.6%
Q1 25
8.6%
Q4 24
6.3%
38.0%
Q3 24
0.5%
-25.9%
Q2 24
-6.0%
Capex Intensity
ENOV
ENOV
LRN
LRN
Q3 26
Q4 25
9.7%
0.0%
Q3 25
7.9%
0.0%
Q2 25
7.7%
0.1%
Q1 25
0.0%
Q4 24
9.5%
0.1%
Q3 24
10.1%
0.1%
Q2 24
7.5%
Cash Conversion
ENOV
ENOV
LRN
LRN
Q3 26
1.32×
Q4 25
0.92×
Q3 25
-2.85×
Q2 25
5.81×
Q1 25
0.53×
Q4 24
2.32×
Q3 24
-3.47×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENOV
ENOV

Reconstructive Segment$258.0M47%
Surgical$129.0M23%
Prevention And Recovery$92.6M17%
Other Prevention And Recovery$71.4M13%

LRN
LRN

General Education$357.5M57%
Middle - High School$259.5M41%
Adult$12.9M2%

Related Comparisons